AR032601A1 - UN COMPUESTO DERIVADO DE QUINOLIN -4-IL, MEDICAMENTO QUE CONTIENE UNO O MAS DE DICHO COMPUESTO, PROCEDIMIENTO PARA LA PREPARACIoN DEL COMPUESTO Y EL USO DEL COMPUESTO - Google Patents

UN COMPUESTO DERIVADO DE QUINOLIN -4-IL, MEDICAMENTO QUE CONTIENE UNO O MAS DE DICHO COMPUESTO, PROCEDIMIENTO PARA LA PREPARACIoN DEL COMPUESTO Y EL USO DEL COMPUESTO

Info

Publication number
AR032601A1
AR032601A1 ARP000105238A ARP000105238A AR032601A1 AR 032601 A1 AR032601 A1 AR 032601A1 AR P000105238 A ARP000105238 A AR P000105238A AR P000105238 A ARP000105238 A AR P000105238A AR 032601 A1 AR032601 A1 AR 032601A1
Authority
AR
Argentina
Prior art keywords
compound
alkyl
hydrogen
quinolin
derived
Prior art date
Application number
ARP000105238A
Other languages
English (en)
Inventor
Alexander Alanine
Serge Burner
Bernd Buettelmann
Neidhart Marie Paule Heitz
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR032601A1 publication Critical patent/AR032601A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto derivado de quinolin-4-il de la formula general (1) en donde: R1 es hidrogeno, alquilo C1-4, alcoxilo C1-4, hidroxilo, amino, nitro, ciano, alquilo C1-4 amino, di-alquil-amino C1-4 o halogeno; R2 es hidrogeno, alquilo C1-4, amino, pirrolidin-3-ol. pirrolidin-2-il-metanol o -NHCH2CHROH; R3 es hidrogeno o halogeno; R es hidrogeno, alquilo C1-4 o -CH2OH; n es 1 o 2, y a sus sales de adicion de ácido farmacéuticamente aceptables. El compuesto es un bloqueador selectivo de subtipo receptor del NMDA (N-metil-D-aspartato), que tienen funcion clave en modular actividad y plasticidad neuronal en procesos de induccion que son fundamentales en el desarrollo de CNS, así como aprendimiento y formacion de la memoria. También se divulga un medicamento que contiene uno o más del compuesto derivado de quinolin-4-il, un procedimiento para la preparacion del compuesto y el uso del compuesto para el tratamiento de enfermedades.
ARP000105238A 1999-10-08 2000-10-05 UN COMPUESTO DERIVADO DE QUINOLIN -4-IL, MEDICAMENTO QUE CONTIENE UNO O MAS DE DICHO COMPUESTO, PROCEDIMIENTO PARA LA PREPARACIoN DEL COMPUESTO Y EL USO DEL COMPUESTO AR032601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99120131 1999-10-08

Publications (1)

Publication Number Publication Date
AR032601A1 true AR032601A1 (es) 2003-11-19

Family

ID=8239160

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105238A AR032601A1 (es) 1999-10-08 2000-10-05 UN COMPUESTO DERIVADO DE QUINOLIN -4-IL, MEDICAMENTO QUE CONTIENE UNO O MAS DE DICHO COMPUESTO, PROCEDIMIENTO PARA LA PREPARACIoN DEL COMPUESTO Y EL USO DEL COMPUESTO

Country Status (26)

Country Link
US (1) US6339093B1 (es)
EP (1) EP1090917B1 (es)
JP (1) JP3385318B2 (es)
KR (1) KR100398562B1 (es)
CN (1) CN1162424C (es)
AR (1) AR032601A1 (es)
AT (1) ATE313538T1 (es)
AU (1) AU777881B2 (es)
BR (1) BR0004709A (es)
CA (1) CA2322309C (es)
DE (1) DE60024947T2 (es)
DK (1) DK1090917T3 (es)
EG (1) EG23872A (es)
ES (1) ES2254095T3 (es)
HR (1) HRP20000652A2 (es)
HU (1) HUP0003938A2 (es)
ID (1) ID27526A (es)
IL (1) IL138916A0 (es)
MA (1) MA26753A1 (es)
MX (1) MXPA00009771A (es)
NO (1) NO20005031L (es)
NZ (1) NZ507303A (es)
PE (1) PE20010660A1 (es)
PL (1) PL343057A1 (es)
TR (1) TR200002893A2 (es)
ZA (1) ZA200005447B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339093B1 (en) * 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
EP1436258A4 (en) * 2001-03-08 2005-03-23 Univ Emory ANTAGONISTS OF THE NMDA RECEPTOR DEPENDENT OF PH
US6831087B2 (en) 2001-11-09 2004-12-14 Hoffmann-La Roche Inc. Pyridine substituted isoquinoline derivatives
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
BRPI0812816B8 (pt) * 2007-06-18 2021-05-25 Richter Gedeon Nyrt compostos derivados de sulfonil-quinolina, ligantes com preferência para subtipo de receptor mglur1 e mglur5, processos para a preparação dos referidos compostos, formulação farmacêutica compreendedo os referidos compostos e uso dos mesmos
CN101815518B (zh) * 2007-06-29 2013-01-09 埃莫里大学 用于神经保护的nmda受体拮抗剂
US20100267712A1 (en) * 2007-09-27 2010-10-21 The United States of America, as represented by the Secretary, Department of Health and Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
ES2849560T3 (es) * 2016-05-04 2021-08-19 Genoscience Pharma Sas Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas
ES2975336T3 (es) 2016-12-22 2024-07-04 Novartis Ag Moduladores del receptor NMDA y usos de los mismos
PE20210948A1 (es) 2018-08-03 2021-05-24 Cadent Therapeutics Inc Moduladores del receptor nmda heteroaromatico y usos de los mismos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8409745D0 (en) * 1984-04-14 1984-05-23 Beecham Group Plc Active compounds
US4560692A (en) * 1984-07-18 1985-12-24 Hoffmann-La Roche Inc. 4-Piperidino-2-phenylquinolines
GB8716972D0 (en) * 1987-07-17 1987-08-26 Pfizer Ltd Treatment of cardiac arrhythmias
JPH0262875A (ja) 1988-05-23 1990-03-02 Wakunaga Pharmaceut Co Ltd 新規イソインドリン誘導体
US4992448A (en) * 1989-10-24 1991-02-12 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
US5304554A (en) * 1990-04-27 1994-04-19 Emory University 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation
GB9203798D0 (en) * 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
GB9305644D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
US5567718A (en) * 1994-08-11 1996-10-22 Hoechst Marion Roussel Inc. 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US6339093B1 (en) * 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives

Also Published As

Publication number Publication date
ATE313538T1 (de) 2006-01-15
BR0004709A (pt) 2001-06-12
AU6410000A (en) 2001-04-12
AU777881B2 (en) 2004-11-04
HUP0003938A2 (hu) 2002-11-28
TR200002893A3 (tr) 2001-04-20
ID27526A (id) 2001-04-12
ZA200005447B (en) 2001-04-09
DK1090917T3 (da) 2006-04-24
HU0003938D0 (en) 2000-12-28
NO20005031D0 (no) 2000-10-06
DE60024947T2 (de) 2006-09-21
PE20010660A1 (es) 2001-06-26
EP1090917A1 (en) 2001-04-11
CA2322309C (en) 2008-05-20
CA2322309A1 (en) 2001-04-08
MA26753A1 (fr) 2004-12-20
HRP20000652A2 (en) 2001-12-31
EP1090917B1 (en) 2005-12-21
JP2001114777A (ja) 2001-04-24
IL138916A0 (en) 2001-11-25
TR200002893A2 (tr) 2001-04-20
KR100398562B1 (ko) 2003-09-19
KR20010050915A (ko) 2001-06-25
PL343057A1 (en) 2001-04-09
CN1162424C (zh) 2004-08-18
MXPA00009771A (es) 2002-10-23
CN1304936A (zh) 2001-07-25
NO20005031L (no) 2001-04-09
DE60024947D1 (de) 2006-01-26
ES2254095T3 (es) 2006-06-16
EG23872A (en) 2007-11-27
US6339093B1 (en) 2002-01-15
NZ507303A (en) 2002-09-27
JP3385318B2 (ja) 2003-03-10

Similar Documents

Publication Publication Date Title
BR0016543A (pt) Novos derivados de piperidina e piperazina
UY28059A1 (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos.
TR200102042T2 (tr) Spiro fropiridinlerin, tedavide faydalı yeni aralkil aminleri.
MX9707453A (es) Derivados de quinazolina.
AR035320A1 (es) Compuestos activadores de hppardelta, composicion farmaceutica, su uso en la preparacion de medicamentos, metodo para el tratamiento de enfermedades mediadas por hppardelta
TW200621762A (en) Novel compounds
UY27592A1 (es) Nuevo uso
NO960630L (no) Heterocykler anvendelige som neurokinin antagonister
TR200000520A2 (tr) 4-Fenil-piridin türevleri.
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
DE60224172D1 (de) Formanilid-derivative als beta2-adrenorezeptor-agonisten
TR200302214T4 (tr) Psoriasis tedavisi için kullanilan pteridine bileşkenleri
CO5271691A1 (es) Nuevos compuestos
AR032601A1 (es) UN COMPUESTO DERIVADO DE QUINOLIN -4-IL, MEDICAMENTO QUE CONTIENE UNO O MAS DE DICHO COMPUESTO, PROCEDIMIENTO PARA LA PREPARACIoN DEL COMPUESTO Y EL USO DEL COMPUESTO
AR035422A1 (es) Compuestos derivados de imidazol, un medicamento que contiene uno o mas de dichos compuestos, un proceso para la preparacion de dichos compuestos y uso de dichos compuestos.
AR029454A1 (es) Derivados de piperazina sustituidos, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
NO20020282D0 (no) Nytt difenylpiperidinderivat
ATE300541T1 (de) Pyrazolopyridinderivate
UY27474A1 (es) Formulación de dosificación oral de fusion instantanea.
DE60217843D1 (de) Ein dioxinoä2,3-güchinolin-9-carbonsäure derivat als nk3 rezeptor antagonist
ATE384708T1 (de) Piperazinderivate als aktivitätsmodulatoren der chemokinrezeptoren
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
HUP9904030A2 (hu) Tiagabin felhasználása pszichotikus rendellenességek kezelésére alkalmas gyógyszer előállítására

Legal Events

Date Code Title Description
FC Refusal